Inovio Pharmaceuticals is revolutionizing the vaccine industry. Its SynCon vaccines are designed to provide universal protection against known as well as new strains of pathogens such as influenza. The company has Phase I and Phase II vaccine studies underway for possible protection against cervical dysplasia, leukemia, hepatitis C, HIV, and influenza.
The company announced today that it has been selected to receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.
Inovio’s proprietary electroporation delivery platform uses millisecond electrical pulses to dramatically improve cellular uptake of the vaccine and resulting immune responses. Its vaccines for cancer and infectious diseases delivered by this platform have previously demonstrated best in class T-cell and antibody responses in clinical studies.
The company is collaborating in this effort with Dr. Connie Schmaljohn, who is the chief scientist at the U.S. Army Medical Research Institute of Infectious Diseases. The goal of this unique partnership is to develop a device that would provide a means to quickly and painlessly deliver multiple vaccines to U.S. troops stationed around the world. A secondary aim is to possible provide protection to civilian populations against pandemic threats.
For more information about Inovio Pharmaceuticals and its unique, proprietary vaccine delivery technology, please visit www.inovio.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
